infoOh, no. Tu navegador no está actualizado o es incompatible con nuestro sitio.

Continua expandiendo tu conocimiento y complementando tu practica medica diaria. 

Actualiza tu navegador a un version mas reciente o intenta usando las siguientes opciones para navegar de forma eficiente y segura.

{{notificationQuantity}}
  • {{notification.subject}}
    {{notification.title}}
    {{notification.timestamp | calculateTimeInWeeks(' semana',' semanas', 'Esta')}}
app install close

Agrega un acceso directo a Diálogo Roche

app install close

Agrega un acceso directo a Diálogo Roche: presiona y luego agrégalo a tu pantalla de inicio.

CLICAP 2022

26 de enero, 2022

1er Congreso Iberamericano

Lo mejor en Cáncer de Pulmón 2021:

El Congreso nace como una iniciativa académica en conjunto con el Oncólogo Torácico Oscar Arrieta y el Dr. Felipe Couñago realizando una sinergia entre el conocimiento generado en la comunidad científica alrededor del mundo durante el período comprendido entre enero y diciembre de 2021.

Esta fue una actividad organizada en 3 días (26, 27 y 28 de enero de 2022), donde se presentaron médicos de Colombia, Argentina, Costa Rica, Chile, México, Uruguay, Guatemala, Perú y España.

Del 26 al 28 de enero, 2022

Videos del Congreso

 

1er Congreso Iberamericano:
Lo mejor en Cáncer de Pulmón 2021

 

Avalado por: Sociedad Mexicana de Oncología y Sociedad Española de Oncología Radioterápica

Dirigido a: Médicos oncólogos, radio-oncólogos y cirujanos torácicos

Objetivos: Ser una plataforma multidisciplinaria dirigido a médicos jóvenes residentes de las áreas de oncología médica, radiooncología y cirugía torácica, donde médicos especialistas de Iberoamérica puedan exponer y generar un diálogo por medio de foros y mesas de discusión de las mejores investigaciones presentadas en el año 2021.

Puntos de certificación:

  • El Consejo Mexicano de Oncología y la Sociedad Mexicana de Oncología otorgarán un total de 15 puntos.
  • El Consejo Mexicano de Radioterapia otorgará 24 puntos.

Programa

  • 8:00 a.m. (México) 3:00 p.m. (España)

    Bienvenida

    Dr. Oscar Arrieta, MX
    Dr. Felipe Couñago, ES

    60 min.

    Cáncer de Pulmón en Etapa Temprana: cirugía

    Coordinador: Dr. Francisco Corona, MX

    Cirugía I

    8:10 a.m. (México) 3:10 p.m. (España)

    -A Prospective Randomized Comparative Study of Three Guided Bronchoscopic Approaches for Investigating Pulmonary Nodules: The PRECISION-1 Study (Chest 2020; 157 (3): 694-701, doi: 10.1016/j.chest.2019.10.016). -Video-assisted thoracoscopic versus open lobectomy in patients with early- stage lung cancer: One-year results from a randomized controlled trial (VIOLET). ASCO 2021, https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8504

    Ponente: Dr. Enrique Guzmán de Alba, MX

    Cirugía II

    8:20 a.m. (México) 3:20 p.m. (España) (10 minutos)

    -Perioperative Outcome of Robotic Approach versus Manual Videothoracoscopic Major Resection in Patients Affected by Early Lung Cancer: Results of a Randomized Study (ROMAN Study). Front Oncol. 2021; 11: 726408. doi: 10.3389/fonc.2021.726408. -Robot-assisted thoracoscopic surgery versus thoracotomy for c-N2 stage NSCLC: short-term outcomes of a randomized trial. Transl Lung Cancer Res. 2019 Dec; 8(6): 951–958, doi: 10.21037/tlcr.2019.11.31

    Ponente: Dr. Francisco Javier Moradiellos Díez, ES

    Cirugía III

    8:30 a.m. (México) 3:30 p.m. (España) (10 minutos)

    -Uniportal Versus Multiportal Video-Assisted Thoracoscopic Lobectomy for Lung Cancer: An Updated Meta-analysis. Lung 2021 Feb;199(1):43-53. doi: 10.1007/s00408-020-00411-9. -Uniportal versus multiportal video-assisted thoracoscopic anatomical resection for NSCLC: a meta-analysis. J Cardiothorac Surg 15, 238 (2020). https://doi.org/10.1186/s13019-020-01280-2

    Ponente: Dr. Diego González Rivas, ES

    8:40 a.m. (México) 3:40 p.m. (España) (10 minutos)

    Evolución y perspectiva del TNM en Cáncer de Pulmón ¿Dónde estamos y a dónde vamos?

    Ponente: Rami Porta, ES

    8:50 a.m. (México) 3:50 p.m. (España) (20 minutos)

    Discusión

    Todos

    30 min.

    Adyuvancia CPCNP no mutados

    Coordinador: Dr. Ludwing Alexander Bacon Fonseca, GT

    9:10 a.m. (México) 4:10 p.m. (España) (20 minutos)

    -Update IMpower010: Results of a Phase 3 Study of Atezolizumab vs Best Supportive Care After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (BNSCLC). ASCO 2021, https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_-suppl.8500 - IMpower010: Sites of relapse and subse-quent therapy from a phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in resected stage IB-IIIA NSCLC. ESMO Congress 2021. Abstract LBA9. -Revisión adyuvancia en pacientes con CPCNP no mutados: inmunoterapia.

    Ponente: Manuel Cobo, ES

    9:30 a.m. (México) 4:30 p.m. (España) (10 minutos)

    Discusión

    Todos

    20 min.

    Actualización de Biopsia líquida en CPCNP

    Coordinador: Dr. Carlos Aliaga Macha, PE

    9:30 a.m. (México) 4:30 p.m. (España) (10 minutos)

    -Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic. Cells 2021 Jul 28;10(8):1912. doi: 10.3390/cells10081912. -Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol 2021 Oct;16(10):1647-1662. doi: 10.1016/j.jtho.2021.06.017. - Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. Crit Rev Oncol Hematol 2021 May;161:103311. doi: 10.1016/j.critrevonc.2021.103311. - Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. Front Oncol 2020 Dec 16;10:593831. doi: 10.3389/- fonc.2020.593831. - Liquid biopsy for early stage lung cancer moves ever closer. Nat Rev Clin Oncol 2020 Sep;17(9):523-524. doi: 10.1038/s41571-020-0393-z. - Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. Clin Lung Cancer 2020 Sep;21(5):e464-e473. - Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. Clin Lung Cancer 2020 Jan;21(1):e10-e14. doi: 10.1016/j.cllc.2019.09.007

    Ponente: Dr. Christian Rolfo, EU

    9:40 a.m. (México) 4:40 p.m. (España) (10 minutos)

    Discusión

    Todos

    40 min.

    CPCNP adyuvancia EGFR mutados

    Coordinador: Dr. Victor Manuel Oyervides Juárez, MX

    9:50 a.m. (México) 4:50 p.m. (España) (20 minutos)

    -Update ADAURA: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer. N Engl J Med. 2020;383(18):1711-1723, doi:10.1056/NEJMoa2027071 -Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respiratory Medicine 2021; 9 (9): 1021-29. https://doi.org/10.1016/S2213-2600(21)00134-X -IMPACT: Adjuvant gefitinib versus cisplatin/vinorelbine with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial. J Clin Oncol 2021 Nov 2;JCO2101729. doi: 10.1200/JCO.21.01729. -Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol 2021 Mar 1;39(7):713-722. doi: 10.1200/JCO.20.01820. -Revisión adyuvancia en pacientes con CPCNP mutados

    Ponente: Dr. Manuel Dómine Gómez, ES

    10:10 a.m. (México) 5:10 p.m. (España) (10 minutos)

    Discusión

    Todos

    10:20 a.m. (México) 5:20 p.m. (España) (10 minutos)

    Break

    Todos

    50 min.

    Neoadyuvancia CPCNP: Inmunoterapia y EGFR

    Coordinador: Diego Kaen, ES

    10:30 a.m. (México) 5:30 p.m. (España) (20 minutos)

    -Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: LCMC3 Trial Primary Analysis. 2020 WCLC, Abstract PS02.05. https://doi.org/10.1016/j.jtho.2021.01.320 -CheckMate 816: Neoadjuvant Nivolumab + Platinum Chemotherapy for Resectable Stage IB-IIIA NSCLC. ASCO 2021. J Clin Oncol. 2021;39(suppl 15):8503-8503). doi:10.1200/JCO.2021.39.15_suppl.8503 and AACR 2021 Cancer Res 2021;81(13_Suppl):Abstract nr CT003. -Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. The Lancet Oncology 2021; 22 (6): 824-835. https://doi.org/10.1016/S1470-2045(21)00149-2 -Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020 Nov;21(11):1413-1422. - NADIM: Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer

    Ponente: Dr. Oscar Gerardo Arrieta Rodríguez, MX

    10:30 a.m. (México) 5:30 p.m. (España) (20 minutos)

    (NSCLC): A Phase II Multicenter Exploratory Study. Pre-treatment Levels of ctDNA May Be Useful in Future Clinical Trials to Predict Long-Term Survival. 2021 WCLC Abstract OA20.02 and Lancet Oncol 21:1413-1422, 2020. -Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. - Pathological Response is an Independent Factor of Overall Survival and Disease-free Survival After Neoadjuvant Durvalumab in Resectable Nonsmall Cell Lung Cancer (NSCLC) in the IFCT-1601 IONESCO Phase Il Trial. ESMO Meeting 2021 Annals of Oncology (2021) 32 (suppl_5): S931-S938. 10.1016/annonc/annonc727 -SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. -Neoadjuvant immune checkpoint inhibitors in resectable non-small cell lung cancer: a systematic review. ESMO Open 2021 Oct;6(5):100244. doi: 10.1016/j.esmoop.2021.100244. - Revisiting neoadjuvant therapy in non-small cell lung cancer. The Lancet Oncology 2021; 22 (11): 501-516. https://- doi.org/10.1016/S1470-2045(21)00383-1

    Ponente: Dr. Oscar Gerardo Arrieta Rodríguez, MX

    10:50 a.m. (México) 5:50 p.m. (España) (10 minutos)

    - A phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutant non-small cell lung cancer: updated results. Presented at: 2021 World Conference on Lung Cancer. Abstract P26.02. -EMERGING: A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of GC as (Neo)Adjuvant Treatment in Stage IIIA-N2 NSCLC With Sensitizing EGFR Mutation in Exon 19 or 21. ASCO 2021, https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8502 - Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer. Transl Lung Cancer Res. 2021 Jan;10(1):607-621. doi: 10.21037/tlcr-20-780. - Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials. Front Oncol. 2021 Jan 12;10:586596. doi: 10.3389/- fonc.2020.586596.

    Dr. Gonzalo Recondo, AR

    11:00 a.m. (México) 6:00 p.m. (España) (20 minutos)

    Discusión

    Todos

    30 min.

    Radioterapia adyuvante en pIIIA-N2

    Coordinador: Dra. Mónika Blake Cerda, MX

    11:10 a.m. (México) 6:10 p.m. (España) (20 minutos)

    -An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART. Lancet Oncol 2021 Dec

    Ponente: Dr. Javier Serrano, MX

    11:10 a.m. (México) 6:10 p.m. (España) (20 minutos)

    14;S1470-2045(21)00606-9. doi: 10.1016/S1470-2045(21)00606-9. -Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy. The Phase 3 PORT-C Randomized Clinical Trial. JAMA Oncol 2021 Aug 1;7(8):1178-1185. doi: 10.1001/jamaoncol.2021.1910. -Revisión evidencia Radioterapia adyuvante

    Ponente: Dr. Javier Serrano, MX

    11:30 a.m. (México) 6:30 p.m. (España) (10 minutos)

    Discusión

    Todos

    30 min.

    CPCNP localmente avanzado irresecable: PACIFIC

    Coordinador: Dra. Dolores de la Mata, MX

    11:40 a.m. (México) 6:40 p.m. (España) (20 minutos)

    -PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC. ASCO 2021.  https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8511 -Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6). European Lung Cancer Congress 2021. Journal of Thoracic Oncology (2021) 16 (suppl_4): S737-S747 -PACIFIC-R: real-world characteristics of unresectable Stage III NSCLC patients treated with durvalumab after chemoradiotherapy. European Lung Cancer Congress 2021. Journal of Thoracic Oncology (2021) 16 (suppl_4): S737-S747. 

    Ponente: Dr. David Vicente Baz, ES

    11:40 a.m. (México) 6:40 p.m. (España) (20 minutos)

    - S-REAL: Características de los pacientes con CPNM estadio III irresecable tratados con Durvalumab tras Quimiorradioterapia dentro del Programa de Medicamentos de Uso Especial en España PACIFIC. SEOM 2021 O-22.

    Ponente: Dr. David Vicente Baz, ES

    12:00 a.m. (México) 7:00 p.m. (España) (10 minutos)

    Discusión

    Todos

    30 min.

    CPCNP locamente avanzado irresecable: Papel inmunoterapia más allá del PACIFIC

    Coordinador: Dr. Luis Mas Pérez, PE

    12:10 a.m. (México) 7:10 p.m. (España) (20 minutos)

    -Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. -A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST). ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741 -The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. J Thorac Oncol 2021 Aug;16(8):1392-1402. doi: 10.1016/j.jtho.2021.04.019.

    Ponente: Dr. Claudio Martín, AR

    12:10 a.m. (México) 7:10 p.m. (España) (20 minutos)

    -Real-World Treatment Patterns and Clinical Outcomes in Patients with Stage III NSCLC: Results of KINDLE, a multicountry observational study. J Thorac Oncol 2021; 16 (10): 1733-1744. -Revisión inmunoterapia en enfermedad localmente avanzado en CPCPNP: más allá del PACIFIC

    Ponente: Dr. Claudio Martín, AR

    12:30 a.m. (México) 7:30 p.m. (España) (10 minutos)

    Discusión

    Todos

    12:40 p.m. (México) 7:40 p.m. (España)

    Cierre de Jornada e introducción siguiente día

    Dr. Felipe Couñago Lorenzo, ES

  • 8:00 a.m. (México) 3:00 p.m. (España) 

    Bienvenida e Introducción día 2 

    Dr. Oscar Arrieta Rodríguez, MX

    30 min.

    Screening Cáncer de Pulmón

    Dra. Marisol Arroyo Hernández, MX

    8:00 a.m. (México) 3:00 p.m. (España)

    The TALENT Study. Abstract PS01.02. Presented at World Conference on Lung Cancer Virtual Conference, 2020 J Thorac Oncol. 2021;16(3):S58. -Defining High Risk. Abstract ES 12.02. WCLC 2020. https://www.jto.org/action/showPdf?pii=S15560864%2821%2900073-3 - Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. The LANCET Regional Health 2021; 10: 100179. https://doi.org/10.1016/j.lanepe.2021.100179. -Comparing U.S. Preventive Services Task Force 2013 versus 2021 lung cancer screening eligibility. ASCO 2021 Abstract 13. https://meetinglibrary.asco.org/record/201698/abstract -USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2021 Dec 10:S1470-2045(21)00590-8. doi: 10.1016/S1470-2045(21)00590-8. -Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA. 2021 Mar 9;325(10):988-997. doi:

    Dra. Lucía Viola Muñoz, CO

    8:00 a.m. (México) 3:00 p.m. (España)

    10.1001/jama.2021.1077. -Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. J Clin Oncol 2021 Aug 10;39(23):2574-2585. doi: 10.1200/JCO.20.02574. -Low-Dose Chest Computed Tomographic Screening and Invasive Diagnosis of Pulmonary Nodules for Lung Cancer in Never-Smokers. WCLC 2020. Abstract MA05.05. https://www.jto.org/action/showPdf?pii=S1556-0864%2821%2900211-2 -Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST. WCLC 2020 Abstract MA05.08. https://www.jto.org/action/showPdf?pii=S15560864%2821%2900211-2 -Mobile low-dose computerized tomography (LDCT): Three-year follow up of solution for early diagnosis of lung cancer in under-served populations. ASCO 2021 Abstract 6507. https://meetinglibrary.asco.org/record/201551/abstract -Differences in Detection Patterns, Characteristics, and Outcomes of Central and Peripheral Lung Cancers in Low-Dose CT Screening. WCLC 2021 Abstract OA19.03. -Lung Cancer Detected By Screening, Incidental Lung Nodule Program and Neither: A Prospective Observational Study. WCLC 2021 Abstract MA10.02 - Balance Between Decreased False Positives and Delayed Diagnosis in Lung Cancer Screening. WCLC 2021 Abstract MA10.03 - Reflections on the Implementation of Low-dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain. 2021 DOI: 10.1016/j.arbr.2017.08.006

    Dra. Lucía Viola Muñoz, CO

    8:30 a.m. (México) 3:30 p.m. (España) (10 minutos)

    Discusión

    Todos

    30 min.

    CPCNP localmente avanzado: Radioterapia

    Coordinador: Dr. Felipe Couñago Lorenzo, ES

    8:40 a.m. (México) 3:40 p.m. (España) (20 minutos)

    -Predictors of Pneumonitis After Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer. Int J Radiat Oncol Biol Phys 2021 Dec 1;111(5):1176-1185. doi: 10.1016/j.ijrobp.2021.07.1691. -Highlights ASTRO 2021: -Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. JAMA Oncol 2021 Oct 1;7(10):1497-1505. doi: 10.1001/jamaoncol.2021.3186. -A phase 2 trial of primary tumor SBRT Boost prior to concurrent chemoradiation for locally-Advanced Non-Small Cell Lung Cancer (LA NSCLC). Int J Radiat Oncol, Biol Phys 2021; 111 (3) S1: S90. -Cardiac Radiation Dose and Patients Risk Factors for predicting major adverse cardiac events in lung cancer patients. ASTRO 2021

    Ponente: Dr. Federico Maldonado Magos, MX

    9:00 a.m. (México) 4:00 p.m. (España) (10 minutos)

    Discusión

    Todos

    50 min.

    CPCNP avanzado no mutados: inmunoterapia (1)

    Coordinador: Dr. Jerónimo Rafael Rodríguez Cid, MX

    9:10 a.m. (México) 4:10 p.m. (España) (20 minutos)

    -First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. -First-line nivolumab plus ipilimumab in advanced non-small cell lung cancer: 4-year outcomes from the randomized open-label, Phase 3, Checkmate 227. ASCO 2021. J Thorac Oncol 2021 Oct 12;S1556-0864(21)03207-X. -Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2021 Sep;32(9):1137-1147. -IMpower 150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups with EGFR Mutations or Metastases in the Liver or the Brain. J Thorac Oncol 2021. https://doi.org/10.1016/j.jtho.2021.09.014 -Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KN 021, 189 and 407. J Thorac Oncol 2021 Nov;16(11):1883-1892. doi: 10.1016/j.jtho.2021.06.020.

    Ponente: Dr. Luis Paz-Ares, ES

    9:30 a.m. (México) 4:30 p.m. (España) (20 minutos)

    -Atezolizumab vs Platinum-based Chemo in Blood-based Tumour Mutational Burden-positive (bTMB+) Patients with First-line (1L) Advanced/metastatic (m) NSCLC: Results of the Blood First Assay Screening Trial (BFAST) Phase Ill Cohort C. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 - EMPOWER-Lung 3: Cemiplimab in Combination with Platinum Doublet Chemotherapy for First Line (1L) Treatment of Advance Non-Small Cell Lung Cancer (NSCLC). ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741 -Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. J Clin Oncol 2021 Jul 20;39(21):2327-2338. doi: 10.1200/JCO.20.03579. -Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JAMA Oncol 2021 Jun 1;7(6):937-939. doi: 10.1001/jamaoncol.2021.0546.

    Ponente: Dr. Luis E. Raez, EU

    9:50 a.m. (México) 4:50 p.m. (España) (20 minutos)

    Discusión

    Todos

    40 min.

    CPCNP avanzado no mutados: inmunoterapia (2) 

    Coordinador: Dr. Osvaldo Aren, UY

    9:30 a.m. (México) 4:30 p.m. (España) (20 minutos)

    Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer. Clin Cancer Res 2021 Oct 22. doi: 10.1158/1078-0432.CCR-21-2649. -Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol 2021 Dec;32(12):1597-1607. doi: 10.1016/j.annonc.2021.08.2151. -Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol 2021 Nov;32(11):1391-1399. doi: 10.1016/j.annonc.2021.08.1744. -IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 2021 Jun;32(6):736-745. doi: 10.1016/j.annonc.2021.02.016. -Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res 2021 Sep 15;27(18):5131-5140. doi: 10.1158/1078-0432.CCR-21-0921 - Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2021 Dec;22(12):1740-1751. doi: 10.1016/S1470-2045(21)00584-2

    Ponente: Dra. Carmen Pupareli, AR

    10:20 a.m. (México) 5:20 p.m. (España) (10 minutos)

    -Activity of OSE-2101 in HLA-A2+ Non-Small Cell Lung Cancer Patients After Failure to Immune Checkpoint Inhibitors (IO): Final Results of Phase III Atalante -1 Randomized Trial. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741 -Cityscape: Updated Analysis and Patient-Reported Outcomes (PROs) from of CITYSCAPE: A Randomized, Double-Blind, Phase II Study of the anti-TIGIT Antibody Tiragolumab + Atezolizumab (TA) Versus Placebo + Atezo (PA) as First-Line Treatment For PD-L1+ NSCLC. ESMO Immuno-Oncology 2021 Abstract LBA2 -First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Ann Oncol 2021 Nov 18;S0923-7534(21)04776-1. doi: 10.1016/j.annonc.2021.11.002. - Atezo Brain: non-randomized phase II clinical trial of atezolizumab combined with carboplatin plus pemetrexed in chemotherapy naïve patients with advanced non-squamous NSCLC with untreated brain metastases. 2021 WCLC. Abstract OA09.02 https://doi.org/10.1016/j.jtho.2021.08.062

    Ponente: Dr. Delvys Rodríguez, ES

    10:30 a.m. (México) 5:30 p.m. (España) (20 minutos)

    Discusión

    Todos

    50 min.

    CPCNP avanzado: EGFR 

    Coordinador: Dr. Mauricio Cuello, CL

    10:50 a.m. (México) 5:50 p.m. (España) (20 minutos)

    - Bevacizumab + Erlotinib vs Erlotinib Alone as First-Line Treatment of Patients with EGFR Mutated Advanced Non-Squamous NSCLC: Final Analysis of the Multicenter, Randomized, Phase IlI BEVERLY Trial. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 - Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med 2021 Aug 26;S2213-2600(21)00166-1. -RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 2021 Jul 22. doi: 10.1158/1078-0432.CCR-21-0273. - Amivantamab Monotherapy and in Combination with lazertinib in Post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS Study. ESMO 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 -Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. JAMA Oncol 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758. -A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol 2021 Nov 26;S0923-7534(21)04825-0. doi: 10.1016/j.annonc.2021.11.010.

    Ponente: Dr. Rafael Rosell

    11:10 a.m. (México) 6:10 p.m. (España) (10 minutos)

    --AENEAS: Phase III Trial of First-line Aumolertinib vs Gefitinib in Advanced EGFR-Mutated NSCLC. ASCO 2021. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.9013 -Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov 2021 Sep 21; candisc.0715.2021. -ORCHARD Osimertinib + Savolitinib Interim Analysis: A Biomarker-Directed Phase II Plataform Study in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Disease has Progressed on First-Line (1L) Osimertinib. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 - Phase 1b Study of Pelcitoclax (APG-1252) in Combination with Osimertinib in Patients with EGFR TKI-resistant NSCLC. 2021 WLCL https://doi.org/10.1016/j.jtho.2021.08.115 -A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clin Cancer Res 2021 Dec 17;clincanres.3194.2021. doi: 10.1158/1078-0432.CCR-21-3194. -Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). Clin Cancer Res 2021 Feb 1;27(3):704-712. doi: 10.1158/1078-0432.CCR-20-3063.

    Dr. Luis Lara Mejía, MX

    11:10 a.m. (México) 6:10 p.m. (España) (10 minutos)

    - Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study. ESMO 2021 Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

    Dr. Luis Lara Mejía, MX

    11:20 a.m. (México) 6:20 p.m. (España) (20 minutos)

    Discusión

    Todos

    11:40 a.m. (México) 6:40 p.m. (España) (10 minutos)

    Break

    Todos

    30 min.

    CPCNP avanzado: EGFR exon 20

    Coordinador: Dra. Pamela Soberanis, MX

    11:10 a.m. (México) 6:10 p.m. (España) (10 minutos)

    -Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol 2021 Dec 1;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761. - Mobocertinib in EGFR Exon 20 Insertion-positive Metastatic NSCLC Patients with Disease Control on Prior EGFR TKI Therapy. WCLC 2021. https://doi.org/10.1016/j.jtho.2021.08.082 - Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.01.284

    Dr. Jordi Remón, ES

    11:10 a.m. (México) 6:10 p.m. (España) (10 minutos)

    - High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from a phase 2 multicenter study, POSITION20. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 - Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.297 - Phase 1 Studies of DZD9008. an Oral, Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon 20 Insertion Mutation. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.083

    Dr. Jordi Remón, ES

    12:10 a.m. (México) 7:10 p.m. (España) (10 minutos)

    Discusión

    Todos

    30 min.

    CPCNP avanzado: MET

    Dr. Suraj Samtani, CL

    12:20 p.m. (México) 7:20 p.m. (España) (20 minutos)

    -Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res 2021 Nov 17. doi: 10.1158/1078-0432.CCR-21-2733. - Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients with previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.085 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS. 2021 WCLC http://dx.doi.org/10.1016/j.jtho.2021.08.084

    Ponente: Dra. Rosario García Campelo, ES

    12:20 p.m. (México) 7:20 p.m. (España) (20 minutos)

    -Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med 2021 Oct;9(10):1154-1164. doi: 10.1016/S2213-2600(21)00084-9. - Real World Next-Generation Sequencing and Treatment Patterns in Non-Small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations. ESMO Meeting 2021 Abstract 1259P -MET-driven acquired resistance in fusion-positive NSCLC. 2021 WCLC. https://doi.org/10.1016/j.jtho.2021.08.113

    Ponente: Dra. Rosario García Campelo, ES

    12:40 p.m. (México) 7:40 p.m. (España) (10 minutos)

    Discusión

    Todos

    30 min.

    CPCNP avanzado: otros drivers

    Coordinador: Dr. Luis Cabrera Miranda, MX

    12:50 p.m. (México) 7:50 p.m. (España) (10 minutos)

    -Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. - Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med 2021 Sep 18. doi: 10.1056/NEJMoa2112431. - Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol 2021 Nov 29;JCO2101323. doi: 10.1200/JCO.21.01323.

    Ponente: Dr. Bartomeu Masutti, ES

    12:50 p.m. (México) 7:50 p.m. (España) (10 minutos)

    -Efficacy of ICI Alone or in Combination with Chemotherapy in NSCLC harboring ERBB2 Mutations. J Thorac Oncol 2021 Nov;16(11):1952-1958. doi: 10.1016/j.jtho.2021.06.025. -Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021 Jul;22(7):959-969. doi: 10.1016/S1470-2045(21)00247-3. -Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res 2021 Aug 1;27(15):4160-4167. doi: 10.1158/1078-0432.CCR-21-0800.

    Ponente: Dr. Bartomeu Masutti, ES

    1:00 p.m. (México) 8:00 p.m. (España) (10 minutos)

    -Acquired Resistance to KRAS G12C Inhibition in Cancer. N Engl J Med 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281. -Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. -Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. J Clin Oncol 2021 Sep 1;39(25):2791-2802. doi: 10.1200/JCO.20.03307. -Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer. Lung Cancer 2021 Jan;151:53-59. doi: 10.1016/j.lungcan.2020.11.023. -NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. Clin Cancer Res 2021 Feb 1;27(3):877-888. doi: 10.1158/1078-0432.CCR-20-1985

    Ponente: Dra. Ivana Sullivan, ES

    1:00 p.m. (México) 8:00 p.m. (España) (10 minutos)

    - TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors. WCLC 2021. DOI: https://doi.org/10.1016/j.jtho.2021.08.118

    Ponente: Dra. Ivana Sullivan, ES

    1:10 p.m. (México) 8:10 p.m. (España) (10 minutos)

    Discusión

    Todos

    30 min.

    CPCNP avanzado ALK+

    Coordinador: Dr. Mauricio Burotto, CL

    1:20 p.m. (México) 8:20 p.m. (España) (20 minutos)

    -Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol 2021 Nov 1;7(11):1617-1625. doi: 10.1001/jamaoncol.2021.3523. -Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 2021 May;32(5):620-630. doi: 10.1016/j.annonc.2021.02.012. - Pembrolizumab in Combination with Platinum-based Chemotherapy in Recurrent EGFR/ALK+ Non-Small Cell Lung Cancer (NSCLC). 2021 WCLC Abstract OA09.03 https://doi.org/10.1016/j.jtho.2021.08.063 - Co-occurring CDKN2A/B alteration is associated with worse survival outcomes in advanced ALK-positive non-small cell lung cancer. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.479

    Ponente: Javier De Castro, ES

    1:20 p.m. (México) 8:20 p.m. (España) (20 minutos)

     - B-FAST: Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. J Thorac Oncol 2021 Dec;16(12):2040-2050. doi: 10.1016/j.jtho.2021.07.008. -Editorial: Optimized Alectinib Dose Regimen for Treatment for Patients with ALK-Positive NSCLC Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence. Clin. Pharmacol. Ther.110, 1164 (2021). https://doi.org/10.1002/cpt.2372.

    Ponente: Javier De Castro, ES

    1:40 p.m. (México) 8:40 p.m. (España) (10 minutos)

    Discusión

    Todos

    1:50 p.m. (México) 8:50 p.m. (España)

    Cierre de Jornada e introducción siguiente día

    Dr. Oscar Arrieta Rodríguez, MX

  • 8:00 a.m. (México) 3:00 p.m. (España)

    Bienvenida e Introducción día 3

    Dr. Felipe Couñago Lorenzo, ES

    30 min.

    Radioterapia en CPCNP avanzado

    Coordinador: Dr. Ernest Nadal, ES

    8:10 a.m. (México) 3:10 p.m. (España) (20 minutos)

    - Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet Respiratory Medicine 2021; 9 (5): P467-75. https://doi.org/10.1016/S2213-2600(20)30391-X -Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2021 Jan 1;7(1):92-106. doi: 10.1001/jamaoncol.2020.6146. -Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II). JAMA Oncol 2021 Oct 1;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. -Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol 2021 Jul;22(7):1023-1033. doi: 10.1016/S1470-2045(21)00196-0. -Highlights ASTRO 2021:

    Ponente: Dr. Javier Luna, ES

    8:10 a.m. (México) 3:10 p.m. (España) (20 minutos)

    - A randomised phase 2 trial of nivolumab and SBRT in advanced NSCLC, progressing after first or second-line chemotherapy (NIVORAD). -Stereotactic body radiotherapy with biologically equivalent dose >150Gy is associated with improved local control in patients with squamous but not non-squamous cell carcinoma of the lung: a multi-institutional analysis. -Targeted high-dose radiation therapy led to a fivefold improvement in progression-free survival for patients with oligoprogressive lung cancer. -The potential for individualized SABR dosing to treat lung tumours.

    Ponente: Dr. Javier Luna, ES

    8:30 a.m. (México) 3:30 p.m. (España) (10 minutos)

    Discusión

    Todos

    30 min.

    CPCP enfermedad limitada

    Coordinador: Dr. Francisco Lozano Ruíz, MX

    8:40 a.m. (México) 3:40 p.m. (España) (20 minutos)

    -Mature outcomes of 61,2 Gy Concomitant Boost Thoracic Radiotherapy in Limited Stage small cell lung cancer LSSCLC: CALGB 30610 Alliance/RTOG 0538. ASCO 2021 https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8505 -Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). ASCO 2021 https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.9007

    Ponente: Dra. Nuria Rodríguez de Dios, ES

    8:40 a.m. (México) 3:40 p.m. (España) (20 minutos)

    -Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study. J Thorac Oncol 2021 May;16(5):840-849. doi: 10.1016/j.jtho.2020.12.024. -Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol 2022 Jan;33(1):67-79. doi: 10.1016/j.annonc.2021.09.011

    Ponente: Dra. Nuria Rodríguez de Dios, ES

    9:00 a.m. (México) 4:00 p.m. (España) (10 minutos)

    Discusión

    Todos

    30 min.

    CPCP enfermedad extensa 

    Coordinador: Dr. David Heredia

    9:10 a.m. (México) 4:10 p.m. (España) (20 minutos)

    - Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. - IMpower133: exploratory analysis of maintenance therapy in patients with ES-SCLC. 2020 WCLC. - Impower133: gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo). ESMO Meeting 2021.

    Ponente: Dr. Santiago Ponce Aix , ES

    9:10 a.m. (México) 4:10 p.m. (España) (20 minutos)

    -Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. J Clin Oncol 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212. -Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol 2021 May;32(5):631-641. doi: 10.1016/j.annonc.2021.01.071.

    Ponente: Dr. Santiago Ponce Aix, ES

    9:30 a.m. (México) 4:30 p.m. (España) (10 minutos)

    Discusión

    Todos

    9:40 a.m. (México) 4:40 p.m. (España) (10 minutos)

    Break

    Todos

    30 min.

    Mesotelioma

    Coordinador: Dra. Laura Bolaño, MX

    9:50 a.m. (México) 4:50 p.m. (España) (20 minutos)

    -Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol 2021 Feb;22(2):190-197. doi: 10.1016/S1470-2045(20)30606-9. -First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. -Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: Preliminary results from the CONFIRM phase 3 trial. The Lancet Oncology 2021; 22 (11): 1530-40. https://doi.org/10.1016/S1470-2045(21)00471-X

    Ponente: Dra. Dolores Isla, ES

    9:50 a.m. (México) 4:50 p.m. (España) (20 inutos)

    -A Randomized Phase II trial of Oral Vinorelbine as Second-Line Therapy for Patients with Malignant Pleural Mesothelioma. ASCO 2021. https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.8507 -Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2021 Oct;22(10):1438-1447. -Pembrolizumab and Nintedanib for Patients with Advanced Mesothelioma. ESMO Meeting 2021 Annals of Oncology (2021) 32 (suppl_5): S1199-S1204. 10.1016/annonc/annonc730 -A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov 2021 Nov;11(11):2748-2763. doi: 10.1158/2159-8290.CD-21-0407.

    Ponente: Dra. Dolores Isla, ES

    10:10 a.m. (México) 5:10 p.m. (España) (10 minutos)

    Discusión

    Todos

    30 min.

    COVID-19 y neoplasias torácicas 

    Coordinador: Dra. Renata Baez, MX

    10:20 a.m. (México) 5:20 p.m. (España) (20 minutos)

    - Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer 2021 Jul; 157: 109-115. doi: 10.1016/j.lungcan.2021.05.014. - Effect of COVID-19 on Thoracic Oncology Surgery in Spain: A Spanish Thoracic Surgery Society (SECT) Survey. Cancers (Basel) 2021 Jun 9;13(12):2897. doi: 10.3390/cancers13122897.

    Ponente: Dr. Luis Corrales, CR

    10:20 a.m. (México) 5:20 p.m. (España) (20 minutos)

    - Depression, anxiety and distress impact in patients with thoracic malignancies during the COVID-19 pandemic. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.092 - Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies. Oncologist 2021 Dec;26(12):1035-1043. doi: 10.1002/onco.13962. - Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19. Lancet Respir Med. 2021 Aug;9(8):e78-e79. doi: 10.1016/S2213-2600(21)00240-X. - Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer 2021 Oct;160:78-83. doi: 10.1016/j.lungcan.2021.07.002.

    Ponente: Dr. Luis Corrales, CR

    10:40 a.m. (México) 5:40 p.m. (España) (10 minutos)

    Discusión

    Todos

    20 min.

    TImoma y Carcinoma Tímico 

    Coordinador: Dr. Edgar Varela, MX

    10:50 a.m. (México) 5:50 p.m. (España) (10 minutos)

    -Efficacy and Safety of Nivolumab for Patients with Pre-treated Type B3 Thymoma and Thymic Carcinoma: Results from the EORTC-ETOP NIVOTHYM Phase Il Trial. 2021 WCLC https://doi.org/10.1016/j.annonc.2021.08.2147 -Revisión tratamiento neoplasias timo: evidencia hasta el momento.

    Ponente: Dr. Leonardo Rojas, CO

    11:10 a.m. (México) 6:10 p.m. (España) (10 minutos)

    Discusión

    Todos

    90 min

    Actualización Estudios 2021: España y Latinoamérica

    Coordinadores: Dr. Oscar Arrieta, MX  Dr. Felipe Couñago, ES

    11:20 a.m. (México) 6:20 p.m. (España) (30 minutos)

    -Estudios españoles 2021 Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study. Transl Lung Res 2021 Oct;10(10):3902-3911. doi: 10.21037/tlcr-21-559. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. ESmo Open 2021 Oct;6(5):100279. doi: 10.1016/j.esmoop.2021.100279. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. BMC Cancer 2021 Aug 31;21(1):977. doi: 10.1186/s12885-021-08713-8. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. J Immunother Cancer 2021 Aug;9(8):e002804. doi: 10.1136/- jitc-2021-002804.

    Ponente: Dr. Mariano Provencio, ES

    11:20 a.m. (México) 6:20 p.m. (España) (30 minutos)

    Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant chemoimmunotherapy Clin Cancer Res 2021 Nov 1;27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200. Epub 2021 Aug 10. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clin Transl Med 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. Plos One 2021 Jun 2;16(6):e0251761. doi: 10.1371/journal.pone.0251761. Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations Transl Lung Cancer Res 2021 2021 Apr;10(4):1761-1772. doi: 10.21037/tlcr-20-1055. Residential radon and lung cancer characteristics at diagnosis. Int j radiat biol 2021;97(7):997-1002. doi: 10.1080/09553002.2021.1913527. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. BMC Cáncer 2021 Mar 6;21(1):230. doi: 10.1186/s12885-021-07922-5. Small-cell lung cancer in never-smokers. ESMO open 2021 Apr;6(2):100059. doi: 10.1016/j.esmoop.2021.100059. 

    Ponente: Dr. Mariano Provencio, ES

    11:20 a.m. (México) 6:20 p.m. (España) (30 minutos)

    Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Lung Cancer 2021 Mar; 153:25-34. doi: 10.1016/j.lungcan.2021.01.005.

    Ponente: Dr. Mariano Provencio, ES

    11:50 a.m. (México) 6:50 p.m. (España) (30 minutos)

    -Estudios latinoamericanos 2021 -Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. Cancer Discov 2021 Mar;11(3):591-598. doi: 10.1158/2159-8290.CD-20-1165. - A high number of co-current genetic alterations is associated with poor survival in EGFR mutated metastatic NSCLC patients. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.620 - Body mass index predicts benefit from adding metformin to EGFR-TKIs in patients with lung cancer adenocarcinoma: sub analysis from an RCT. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.520 p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. Transl Oncol 2022 Jan;15(1):101276. doi: 10.1016/j.- tranon.2021.101276. -Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma. Front Oncol 2021 Apr 20;11:641975. doi: 10.3389/fonc.2021.641975. 

    Ponente: Dr. Andrés Cardona, CO

    11:50 a.m. (México) 6:50 p.m. (España) (30 minutos)

    -RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. BMC Cancer 2021 Aug 5;21(1):892. doi: 10.1186/s12885-021-08287-5. -Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer 2021 Nov;22(6):510-522. doi: 10.1016/j.cllc.2021.03.014. Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized phase 2 Study (PRoT-BM trial). Int J Radiat Oncol Biol Phys 2021 Aug 1;110(5):1442-1450. -Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. Lung Cancer 2021 May;155:183-190. doi: 10.1016/j.lungcan.2021.01.023. -The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival. Nutr Cancer 2021;73(5):794-801. doi: 10.1080/01635581.2020.1769691. -Failure to EGFR-TKI-based therapy and tumoral progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. Eur J Cancer 2022 Jan;160:189-205. doi: 10.1016/j.ejca.2021.10.032. -Prophylactic Cranial Irradiation in Patients With High-Risk Metastatic Non-Small Cell Lung Cancer: Quality of Life and Neurocognitive Analysis of a Randomized Phase II Study. Int J Radiat Oncol Biol Phys 2021 Sep 1;111(1):81-92. 

    Ponente: Dr. Andrés Cardona, CO

    11:50 a.m. (México) 6:50 p.m. (España) (30 minutos)

    -Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America. Mol Clin Oncol 2022 Jan;16(1):6. doi: 10.3892/mco.2021.2439.

    Ponente: Dr. Andrés Cardona, CO

    12:20 a.m. (México) 7:20 p.m. (España) (10 minutos)

    Discusión

    Todos

    12:30 p.m. (México) 2:30 p.m. (España)

    Despedida y Cierre

    Coordinadores: Dr. Oscar Arrieta, MX  Dr. Felipe Couñago, ES


El presente material puede contener información referida a medicamentos bajo investigación o en indicaciones aún no aprobadas, con el único objetivo de utilización reactiva a consultas recibidas por profesionales de la salud a fin de brindar información médica y/o científica.

Roche no recomienda el uso de ningún producto en cualquier indicación, dosis o vía de administración que no esté claramente mencionado en la información para prescribir del producto aprobado por la autoridad regulatoria local.

Los puntos de vista y opiniones expresadas en este material son exclusiva responsabilidad de los autores y no representan necesariamente las opiniones de Roche.